Organization
Immunogen Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Immunogen Inc.

... ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
... Ph.D., president and CEO of IAVI. "Fortunately, a new generation of HIV immunogen candidates, including eOD-GT8 60mer, is entering clinical trials. These candidates are being ...
... ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
... ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
... ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
... By Companies 8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex 8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc. 8.1.3 Indatuximab Ravtansine/BT-062 - Biotest AG 8.1.4 Anti-PSMA ADC Therapeutic - ...
... agreed to co-develop and co-promote the therapy in the US. Mirvetuximab soravtansine, Immunogen Mirvetuximab soravtansine is an investigative drug for the treatment of folate receptor ...
... ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
... ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) ...
Subscribe now for full coverage on Immunogen Inc.
Start My Free Trial